ASAIO JOURNAL-VOLUME 40

Subject Index

Editor's Note: This index encompasses only the material presented in this issue of ASAIO JOURNAL Volume 40, Numbers 1, 2, and 4. Please consult the July-September issue (Vol. 40, No. 3) for an index of the contents of that body of work.

A

Amino acids, interference of glucose sensing by, 33
Anesthesia, for diaphragmatic hernia repair during extracorporeal membrane oxygenation, 986
Anticoagulation, in continuous renal replacement therapy, 931
Aortic valve, mechanical suitability of pulmonary valve as replacement for, 206
Arterial wall, uptake of ^{3}H-7-cholesterol along, at area of stenosis, 186
Arteriovenous fistula needle technique, for hemodialysis, early development of, 923
Artificial, lung, criteria for, extracorporeal membrane oxygenation and, 109
Artificial heart, total, pulsatile impeller, *in vivo* evaluation of, 213
Artificial lung, criteria for, extracorporeal membrane oxygenation and, 109
Artificial organs, history, environment, and future of, 1
Artificial vision, 919
Assisted circulation, hemorrheology with, sheep model for study of, 959

B

Bacterial biofilm graft infection, immune regulation of, 219
Beta-2 microglobulin, removal in high-flux hemodialysis, in uremic patients, statistical and parametric analysis of, 62
Biofilm graft, bacterial infection of, immune regulation of, 219
Bioprosthetic heart valves
  mechanical suitability of pulmonary valve as aortic valve replacement, 206
  mounting frame to reduce flexural stresses at, 199
  porcine, fixed with epoxy compound, evaluation of, 192
Biventricular bypass, nonpulsatile, effect of respiration in arterial pressure wave in calves with, 981
Blood pump, orbiting scroll, without valves or rotating seals, 41
Breast implants, gel filled, unimplanted, physical characterization of, 943

C

Ca^{2+} concentration, of peritoneal dialysis solutions, regulation of peritoneal and macrophage mesothelial cell activation by, 20
Cardiac assist device, valveless, attached to ventricular apex, 171
Cardiac disease, in chronic uremia, pathophysiology and clinical epidemiology of, 121
Cardiac surgery, circulatory collapse after, heparin coated percutaneous cardiopulmonary support for treatment of, 972
Cardiopulmonary support, percutaneous, heparin coated, for circulatory collapse after cardiac surgery, 972
Cellulose acetate hemodialyzers, thrombogenicity of, *in vitro* and *in vivo* evaluation of, with radiolabeled platelets, 49
Cholesterol, uptake of ^{3}H-7-cholesterol along arterial wall at area of stenosis, 186
Circulation, assisted, hemorrheology with, sheep model for study of, 959
Circulatory collapse, after cardiac surgery, heparin coated percutaneous cardiopulmonary support for treatment of, 972
Circulatory support devices, mechanical, pulsatile power load effects on nickel/cadmium battery cells for, 67
Complement activation, neutrophil lactoferrin release during open heart surgery and, 56
Contamination, of dialysis water and dialysate, 1012
Continuous renal replacement therapy, 928, 940
  anticoagulation issues in, 931
Continuous veno-venous hemofiltration, for acute renal failure, technical considerations in, 936

D

Dialysis, 107. *See also* Hemodialysis; Peritoneal dialysis
  contamination of dialysis water and dialysate and, 1012
  diseases associated with, national surveillance of, 1020
  hemodiafiltration to enhance, 977
  patient outcome and, hypertension and, 130
  slow urea transfer in body during, patient related factors leading to, 164
Diaphragmatic hernia repair, during extracorporeal membrane oxygenation, general anesthesia with isoflurane for, 986

E

Endocarditis, prosthetic valve, outcome in, 176
Enzymatic glucose sensors, long-term performance *in vitro* and *in vivo*, 157
Erythropoietin therapy
  adverse reactions to, 70
  dosage delivery for, 72
  in renal transplantation, 72
Extracorporeal membrane oxygenation
  criteria for artificial lung and, 109

ASAIO JOURNAL-VOLUME 40

Subject Index

Editor's Note: This index encompasses only the material presented in this issue of ASAIO JOURNAL Volume 40, Numbers 1, 2, and 4. Please consult the July-September issue (Vol. 40, No. 3) for an index of the contents of that body of work.

A

Amino acids, interference of glucose sensing by, 33
Anesthesia, for diaphragmatic hernia repair during extracorporeal membrane oxygenation, 986
Anticoagulation, in continuous renal replacement therapy, 931
Aortic valve, mechanical suitability of pulmonary valve as replacement for, 206
Arterial wall, uptake of ^{3}H-7-cholesterol along, at area of stenosis, 186
Arteriovenous fistula needle technique, for hemodialysis, early development of, 923
Artificial, lung, criteria for, extracorporeal membrane oxygenation and, 109
Artificial heart, total, pulsatile impeller, *in vivo* evaluation of, 213
Artificial lung, criteria for, extracorporeal membrane oxygenation and, 109
Artificial organs, history, environment, and future of, 1
Artificial vision, 919
Assisted circulation, hemorrheology with, sheep model for study of, 959

B

Bacterial biofilm graft infection, immune regulation of, 219
Beta-2 microglobulin, removal in high-flux hemodialysis, in uremic patients, statistical and parametric analysis of, 62
Biofilm graft, bacterial infection of, immune regulation of, 219
Bioprosthetic heart valves
  mechanical suitability of pulmonary valve as aortic valve replacement, 206
  mounting frame to reduce flexural stresses at, 199
  porcine, fixed with epoxy compound, evaluation of, 192
Biventricular bypass, nonpulsatile, effect of respiration in arterial pressure wave in calves with, 981
Blood pump, orbiting scroll, without valves or rotating seals, 41
Breast implants, gel filled, unimplanted, physical characterization of, 943

C

Ca^{2+} concentration, of peritoneal dialysis solutions, regulation of peritoneal and macrophage mesothelial cell activation by, 20
Cardiac assist device, valveless, attached to ventricular apex, 171
Cardiac disease, in chronic uremia, pathophysiology and clinical epidemiology of, 121
Cardiac surgery, circulatory collapse after, heparin coated percutaneous cardiopulmonary support for treatment of, 972
Cardiopulmonary support, percutaneous, heparin coated, for circulatory collapse after cardiac surgery, 972
Cellulose acetate hemodialyzers, thrombogenicity of, *in vitro* and *in vivo* evaluation of, with radiolabeled platelets, 49
Cholesterol, uptake of ^{3}H-7-cholesterol along arterial wall at area of stenosis, 186
Circulation, assisted, hemorrheology with, sheep model for study of, 959
Circulatory collapse, after cardiac surgery, heparin coated percutaneous cardiopulmonary support for treatment of, 972
Circulatory support devices, mechanical, pulsatile power load effects on nickel/cadmium battery cells for, 67
Complement activation, neutrophil lactoferrin release during open heart surgery and, 56
Contamination, of dialysis water and dialysate, 1012
Continuous renal replacement therapy, 928, 940
  anticoagulation issues in, 931
Continuous veno-venous hemofiltration, for acute renal failure, technical considerations in, 936

D

Dialysis, 107. *See also* Hemodialysis; Peritoneal dialysis
  contamination of dialysis water and dialysate and, 1012
  diseases associated with, national surveillance of, 1020
  hemodiafiltration to enhance, 977
  patient outcome and, hypertension and, 130
  slow urea transfer in body during, patient related factors leading to, 164
Diaphragmatic hernia repair, during extracorporeal membrane oxygenation, general anesthesia with isoflurane for, 986

E

Endocarditis, prosthetic valve, outcome in, 176
Enzymatic glucose sensors, long-term performance *in vitro* and *in vivo*, 157
Erythropoietin therapy
  adverse reactions to, 70
  dosage delivery for, 72
  in renal transplantation, 72
Extracorporeal membrane oxygenation
  criteria for artificial lung and, 109

diaphragmatic hernia repair during, general anesthesia with isoflurane for, 986
neonatal mortality in premature infants with respiratory failure and, 27
registry report on, 1017

F

FK 506, recovery of renal function from warm ischemic injury in rats and, 964
Food and Drug Administration, guidance sections for medical devices, 138
Fulminant hepatic failure
Hepatix extracorporeal liver assist device for, 83
liver transplantation for, 86

G

Gel filled breast implants, unimplanted, physical characterization of, 943
Glucose sensing, interference of, by amino acids, 33
Glucose sensors, enzymatic, long-term performance *in vitro* and *in vivo*, 157
Glucose transport, transperitoneal, parameter estimation in numerical models of, 1005
Glutathione-peroxidase enzyme, plasma, in hemodialyzed patients, 968
Heart, total artificial, pulsatile impeller, *in vivo* evaluation of, 213

H

Hemodiabsorption, in acute hepatic failure, 80
Hemodiafiltration, to enhance delivered dialysis, 977
Hemodialysis
arteriovenous fistula needle technique for, early development of, 923
high flux, beta-2 microglobulin removal from uremic patients in, statistical and parametric analysis of, 62
percutaneous vessel catheterization for, 17
plasma glutathione-peroxidase enzyme in, 968
thrombogenicity of cellulose acetate hemodialyzers and, *in vitro* and *in vivo* evaluation of, with radiolabeled platelets, 49
Hemofiltration, veno-venous, continuous, for acute renal failure, technical considerations in, 936
Hemorrheology, with assisted circulation, sheep model for study of, 959
Heparin coated percutaneous cardiopulmonary support, for circulatory collapse after cardiac surgery, 972
Hepatix extracorporeal liver assist device, in fulminant hepatic failure, 83
Hollow fiber membrane oxygenators, mathematical model for prediction of rate of oxygen transfer in, 990
Hypertension, dialysis patient outcomes related to, 130

I

Immune regulation, of bacterial biofilm graft infection, 219
Implants, infections and, 216
Infection
bacterial, of biofilm graft, immune regulation of, 219
implants and, 216
thrombosis related to, 226
in artificial organs, 230
Internal ventricular venting loop catheter, as ventricular assist system, 181
Isoflurane, for diaphragmatic hernia repair during extracorporeal membrane oxygenation, 986

K

Kt/V formulas, based on urea mass balance theory, 997

L

Lactoferrin, neutrophil release of, during open heart surgery, complement activation and, 56
Liver failure
acute, hemodiabsorption in treatment of, 80
fulminant
Hepatix extracorporeal liver assist device for, 83
liver transplantation for, 86
strategies for rescue of patients with, 74
plasma exchange as, 77
Liver transplantation, for fulminant hepatic failure, 86

M

Malacoplakia, of prostate, in renal transplant recipient, 238
Mechanical circulatory support devices, pulsatile power load effects on nickel/cadmium battery cells for, 67
Medical devices, Food and Drug Administration guidance sections for, 138
Mesothelial cell activation, peritoneal and macrophage, regulation by peritoneal dialysis solution pH and Ca^{2+} concentration, 20
Microglobulin, removal in high-flux hemodialysis, in uremic patients, statistical and parametric analysis of, 62
Monofilament sutures, polyvinylidene fluoride for, 145

N

Neonatal mortality, in premature infants with respiratory failure, extracorporeal membrane oxygenation and, 27
Neurostimulation, in obstructive sleep apnea, 13
Neutrophils, lactoferrin release by, during open heart surgery, complement activation and, 56
Nickel/cadmium battery cells, for mechanical circulatory support devices, pulsatile power load effects on, 67

O

Obstructive sleep apnea, neurostimulation in, 13
Open heart surgery, neutrophil lactoferrin release during, complement activation and, 56
Orbiting scroll blood pump, without valves or rotating seals, 41
Oxygen transfer, rate of, in hollow fiber membrane oxygenators, mathematical model for prediction of, 990

P

Percutaneous cardiopulmonary support, heparin coated, for circulatory collapse after cardiac surgery, 972
Percutaneous vessel catheterization, for hemodialysis, 17
Peritoneal dialysis
duration of, 24

pH and Ca^{2+} concentration of, regulation of peritoneal and macrophage mesothelial cell activation by, 20
pH, of peritoneal dialysis solutions, regulation of peritoneal and macrophage mesothelial cell activation by, 20
Plasma exchange, as strategy for rescue of patients with liver failure, 77
Platelets, radiolabeled, *in vitro* and *in vivo* evaluation of thrombogenicity of cellulose acetate hemodialyzers with, 49
Polyvinylidene fluoride, for monofilament sutures, 145
Premature infants, with respiratory failure, mortality among, extracorporeal membrane oxygenation and, 27
Prostate, malacoplakia of, in renal transplant recipient, 238
Prosthetic heart valves. *See also* Bioprosthetic heart valves
  prosthetic valve endocarditis and, outcome in, 176
Protein bound toxins, in uremia, 89, 90
Pulmonary valve, mechanical suitability as aortic valve replacement, 206
Pulsatile impeller total artificial heart, *in vivo* evaluation of, 213
Pulsatile power loads, effects on nickel/cadmium battery cells for mechanical circulatory support devices, 67

R

Radiolabeled platelets, *in vitro* and *in vivo* evaluation of thrombogenicity of cellulose acetate hemodialyzers with, 49
Renal failure, acute, continuous veno-venous hemofiltration for, technical considerations in, 936
Renal function, recovery from warm ischemic injury in rats, timing of FK 506 administration and, 964
Renal replacement. *See* Continuous renal replacement therapy
Renal transplantation
  erythropoietin therapy and, 72
  malacoplakia of prostate and, 238
Respiration, effect on arterial pressure wave, in calves with nonpulsatile biventricular bypass, 981
Respiratory failure, in premature infants, extracorporeal membrane oxygenation and, neonatal mortality and, 27
Right ventricular performance, response to decreasing levels of mechanical assistance, evaluation by on-line pressure area relations, 1032

S

Sleep apnea, obstructive, neurostimulation in, 13
Stenosis, uptake of ^{3}H-7-cholesterol along arterial wall at area of, 186
Sutures, monofilament, polyvinylidene fluoride for, 145

T

Thrombogenicity, of cellulose acetate hemodialyzers, *in vitro* and *in vivo* evaluation of, with radiolabeled platelets, 49
Thrombosis, infection related to, 226
  in artificial organs, 230
Total artificial heart, pulsatile impeller, *in vivo* evaluation of, 213
Transperitoneal glucose transport, parameter estimation in numerical models of, 1005

U

Urea mass balance theory, Kt/V formulas based on, 997
Urea transfer, slow, during dialysis, patient related factors leading to, 164
Uremia
  beta-2 microglobulin removal in high-flux hemodialysis in, statistical and parametric analysis of, 62
  chronic, cardiac disease in, pathophysiology and clinical epidemiology of, 121
  protein bound toxins in, 89, 90

V

Valveless cardiac assist device, attached to ventricular apex, 171
Veno-venous hemofiltration, continuous, for acute renal failure, technical considerations in, 936
Ventricular assist systems
  internal ventricular venting loop catheter as, 181
  response of right ventricular performance to decreasing levels of mechanical assistance and, evaluation by on-line pressure area relations, 1032
Vessel catheterization, percutaneous, for hemodialysis, 17
Vision, artificial, 919

Author Index

A

Adachi, Hideo, 40:972
Adams, William A., 40:67
Agishi, Tetsuzo, 40:77
Aiken, Peter A., 40:67
Alter, Miriam J., 40:1020
Anderson, Robert W., 40:990
Antaki, James F., 40:959
Armitage, John M., 40:1032
Ash, Stephen R., 40:80
Atkinson, J. B., 40:986

B

Bambauer, R., 40:1012
Barichello, David L., 40:997
Barrett, Cynthia, 40:27
Bartlett, Robert H., 40:1017
Bellucci, Alessandro G., 40:130
Bergamini, Thomas M., 40:219
Biasioli, Stefano, 40:968
Bishop, N. D., 40:171
Bland, Lee A., 40:1020
Borovetz, Harvey S., 40:959
Boughner, Derek R., 40:206
Bovill, Joseph J., 40:56
Bregman, David, 40:181
Brescia, Michael J., 40:923
Briseno, Samuel, 40:181
Brittian, Kenneth R., 40:219
Broniatowski, Michael, 40:13
Bronskill, Michael, 40:943
Buchwald, Henry, 40:917
Bui, Kim Chi, 40:27
Butler, Kenneth C., 40:959

C

Cacciarelli, Thomas V., 40:964
Campbell, G., 40:199
Campbell, Terry G., 40:109
Canaud, Bernard C., 40:997
Cardou, Alain, 40:145, 40:943
Carozzi, Silvia, 40:20
Cavagnaro, Carlos F., 40:49
Cavalcanti, Gaetano, 40:968
Cavallini, Lucia, 40:968
Caviglia, Pietro Marco, 40:20
Cederlöf, I. O., 40:164
Chang, Yen Lin, 40:62
Charara, Jamal, 40:943
Cheadle, William G., 40:219
Chen, Chun-Kuo, 40:964
Cheng, Chi Hung, 40:62
Chu, Shu-Hsun, 40:213
Chung, Mona, 40:27
Cimino, James E., 40:923
Corpus, Roberto A., 40:219
Cressman, Michael D., 40:977

D

Daugirdas, John T., 40:89
Daum, V., 40:1012
David, Huw, 40:206
Day, Terri-Lynn, 40:33
De Fanti, Emanuela, 40:968
Dehara, Kazuhiko, 40:86
Delaney, Vera B., 40:238
DeLosh, Thomas, 40:1017
Deng, Xiaoyan, 40:186
DeSmet, R., 40:90
Dewanjee, Mrinal K., 40:49
DiGiuseppe, Bonny, 40:997
Dobelle, William H., 40:919
Dodson, S. Forrest, 40:86
Dokainish, M. A., 40:199
Douville, Yvan, 40:145
Duguay, Daniel G., 40:67

E

Elson, Raymond, 40:49
Ericsson, F., 40:164
Ezuddin, Shabbir H., 40:49

F

Favero, Martin S., 40:1020
Flanigan, Michael J., 40:24
Fleury, Danielle, 40:943
Fogh-Andersen, Niels, 40:1005
Friedman, Eli A., 40:107
Fugleberg, Steen, 40:1005
Fukamachi, Kiyotaka, 40:981
Fung, Tsi-Chiang, 40:27

G

Gagnon, R. F., 40:216
Gangitanos, Ernesto, 40:27
Garred, Laurie J., 40:997
Gerosa, Gino, 40:206
Gilligan, Barbara J., 40:157
Golding, Leonard A. R., 40:981
Golper, Thomas A., 40:936
Gorcsan, John, III, 40:1032
Graff, Jesper, 40:1005
Griffith, Bartley P., 40:959, 40:1032
Guidi, Giancesare, 40:968
Guidoin, Robert, 40:145, 40:186, 40:943

H

Hamid, R., 40:986
Harasaki, Hiroaki, 40:981
Harnett, John D., 40:121
Hata, Cary, 40:192
Hoeg, Karen L., 40:219
Hong, Joon H., 40:964
Hoover, Eddie L., 40:56
Hsiong, Cheng Huei, 40:62

I

Ide, Hirofumi, 40:972
Ifudu, Onyekachi, 40:238
Ing, Todd S., 40:70
Ino, Takashi, 40:972
Iwatsuki, Shunzaburo, 40:86

J

Jacobson, S., 40:164
Joffe, Preben, 40:1005
Jung, W. K., 40:1012

K

Kameneva, Marina V., 40:959
Kapadvanjwala, Mansoor, 40:49
Kaplan, Andre A., 40:940
Kawahito, Koji, 40:972
Kelly, James H., 40:83
King, Martin, 40:943
King, Martin W., 40:145, 40:186
Kingsbury, Chris J., 40:192
Kjellstrand, C., 40:164
Kjellstrand, P., 40:164
Kolff, W. J., 40:171
Kolff, Willem J., 40:1
Kormos, Robert L., 40:959, 40:1032
Krucinski, S., 40:199
Kubo, Kazuo, 40:77

L

Laroche, Gaetan, 40:145
Lazarus, J. Michael, 40:70
Lee, Chau Jen, 40:62
Lee, David B. N., 40:72
Leonard, Ronald J., 40:990
Lessard, Roger, 40:943
Lew, Cheryl D., 40:27
Lian, Jong Da, 40:62
Lim, Victoria S., 40:24
Lin, David, 40:192
Logue, Gerald L., 40:56
Luebow, Jens O., 40:157

M

MacLean, Gregory K., 40:67
Mailloux, Lionel U., 40:130
Makhoul, Imad R., 40:27
Mandarino, William A., 40:1032
Manns, Markus, 40:928
Mapp, John, 40:27
Marceau, Daniel, 40:943
Marois, Yves, 40:145, 40:186
Marten, C., 40:171
Martin, Louisette, 40:145
Matsushita, Michiaki, 40:74
McCready, William G., 40:997
Mehta, Ravindra L., 40:931
Mekhjian, Haroutune A., 40:181
Miller, Elaine, 40:1020
Mizuhara, Akihiro, 40:972
Mockros, Lyle F., 40:990
Mohammad, Syed F., 40:226
Mossey, Robert T., 40:130
Moyer, Linda A., 40:1020
Mussivand, Tofy, 40:67

N

Nakagawa, Yoshihiko, 40:77
Nakajima, H., 40:171
Nakazato, Satoshi, 40:77
Napolitano, Barbara, 40:130
Nasini, Maria Grazia, 40:20
Noishiki, Yasuharu, 40:192

O

O'Connor, Brian M., 40:56
Orejola, Wilmo C., 40:181
Ota, Kazuo, 40:77
Otaki, Masaki, 40:176

P

Paganini, Emil P., 40:72, 40:977
Panoutsopoulos, George K., 40:49
Pantalos, G., 40:171
Parfrey, Patrick S., 40:121
Patzer, John F., II, 40:33
Petrosino, Luigi, 40:968
Peyton, James C., 40:219
Pflederer, Timothy A., 40:24
Pietrucci, Angelo, 40:20
Price, Joni, 40:936

Q

Qian, Kun-Xi, 40:213
Quijano, Rodolfo C., 40:192

R

Raza, Syed, 40:56
Rhodes, Rathbun K., 40:157
Richards, G. K., 40:216
Ringoir, S., 40:90
Rohde, Thomas D., 40:917
Rolland, Catherine, 40:943

S

Santoni, Oscar, 40:20
Schauer, M., 40:1012
Schelotto, Claudio, 40:20
Schiavon, Renzo, 40:968
Serafini, Aldo N., 40:49
Sfakianakis, George N., 40:49
Shaldon, Stanley, 40:17
Sharp, M. Keith, 40:41
Shastri, Kaushik A., 40:56
Shelton, A., 40:171
Shen, Shih-Hwa, 40:192
Shults, Mark C., 40:157
Sigler, Miles H., 40:928
Skröder, R., 40:164
Smith, William A., 40:981
Sommer, Bruce G., 40:964
Stephenson, L. W., 40:171
Stern, Mont P., 40:56
Steward, D. J., 40:986
Suguihara, Cleide Y., 40:49
Sumrani, Nabil B., 40:964
Sung, Hsing W., 40:192
Sussman, Norman L., 40:83

T

Teraoka, Satoshi, 40:77
Thomas, G., 40:171
Tokars, Jerome I., 40:1020
Tominaga, Ryuji, 40:981
Tomizawa, Yasuko, 40:192
Topaz, S. R., 40:171
Tracy, Thomas F., Jr., 40:1017
Tu, Roger, 40:192

U

Uchino, Junichi, 40:74
Updike, Stuart J., 40:157
Urban, Elisabeth, 40:145

V

Vanholder, R., 40:90
van Loon, J., 40:171
Vaslef, Steven N., 40:990
Vesely, I., 40:199
Vesely, Ivan, 40:206
Vienken, J., 40:1012
von Heimburg, Don, 40:157

W

Wang, Shoei-Shen, 40:213
Watach, Mary J., 40:959
Watson, John T., 40:138
Wei, Serh S., 40:977
Wilde, J. C. H., 40:171
Witzel, Thomas H., 40:192
Wolfson, Sidney K., Jr., 40:33
Wright, Eugene, 40:977

X

Xu, Weijian, 40:33

Y

Yamaguchi, Atsushi, 40:972
Yao, Shang J., 40:33
Ying-Long, Liu, 40:181

Z

Zambello, Alberto, 40:968
Zhou, Feng, 40:181
Zilleruelo, Gaston E., 40:49

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970: Section 3685. Title 39 United States Code) Date of Filing—October 1, 1994; Title of Publication—ASAIO Journal; Publication No.—10582916; Frequency of Issue—Quarterly; Annual Subscription Price—$180.00; Location of Known Office of Publication—12107 Insurance Way, Suite 114, Hagerstown, MD 21740; Location of the Headquarters or General Business Offices of the Publisher—J. B. Lippincott Company, 227 East Washington Square, Philadelphia, PA 19106; Publisher—American Society for Artificial Internal Organs, Inc., P.O. Box C, Boca Raton, FL 33429-0468; Editor—Eli A. Friedman, MD, Box 52, Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203; Managing Editor—Todd Hummel, 227 East Washington Square, Philadelphia, PA 19106; Owner—American Society for Artificial Internal Organs, Inc., PO Box C, Boca Raton, FL 33429-0468; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—None. A. Total no. copies printed (*net press run*), average 2,925, actual 3,100; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 2,188, actual 1,907; C. Total paid circulation, average 2,188, actual 1,907; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 43, actual 42; E. Total distribution (*sum of C and D*), average 2,231, actual 1,949; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 694, actual 1,151; 2. Returns from news agents, none; G. Total (*sum of E and F—should equal net press runs shown in A*), average 2,925, actual 3,100. I certify that the statements made by me above are correct and complete. Virginia B. Martin, *Vice President.*